首页> 外国专利> Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases

Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases

机译:TNF-A和IL-21双重拮抗剂预防和治疗自身免疫性疾病

摘要

The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
机译:本发明涉及作为TNF-α(α)和IL-21的双重拮抗物的TNFR2-IL21R融合蛋白。包含TNF-α和II-21双重拮抗剂(TNFR2-IL21R融合蛋白)的组合物,被称为自身免疫性类风湿关节炎的一种主要病因,是自身免疫性疾病之一,可以减少炎性细胞因子的分泌,增加抗炎性细胞因子的分泌与TNFR2-Fc和IL21R-Fc等单个蛋白相比,它具有更好的炎症细胞因子和抑制破骨细胞分化的作用。通过增加免疫抑制细胞Treg的表达,本发明的TNFR2-IL21R融合蛋白不仅对CIA小鼠模型中的关节炎具有优异的治疗效果,而且对自身免疫性类风湿性关节炎也具有优异的治疗效果。因此,本发明的TNFR2-IL21R融合蛋白可以有效地用作用于预防和治疗自身免疫疾病的组合物的活性成分。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号